{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:14:12Z","timestamp":1790158452497,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["S2010\/ BMD-2422 AGES"],"award-info":[{"award-number":["S2010\/ BMD-2422 AGES"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millennium Pharmaceuticals"},{"name":"Innova Pharma-Recordati Group"},{"name":"Janssen Pharmaceutica NV"},{"name":"Sunovion Pharmarmaceuticals"},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"University of Copenhagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria"},{"DOI":"10.13039\/501100006751","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Madrid Regional Government"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.euroneuro.2020.03.010","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T07:25:31Z","timestamp":1586589931000},"page":"76-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning"],"prefix":"10.1016","volume":"34","author":[{"given":"Paola","family":"Bucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armida","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Winter","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Baandrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Dazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsime","family":"Demjaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8538-3175","authenticated-orcid":false,"given":"Covadonga M.","family":"D\u00edaz-Caneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Maria","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte Y.","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rodriguez-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Vignapiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Galderisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2020.03.010_bib0001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2016.05.015","article-title":"Treatment of negative symptoms: where do we stand, and where do we go?","volume":"186","author":"Aleman","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0002","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/schbul\/sbj056","article-title":"An industry perspective on the nimh consensus statement on negative symptoms","volume":"32","author":"Alphs","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eurpsy.2003.10.004","article-title":"The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms","volume":"19","author":"Arango","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.schres.2006.09.026","article-title":"Cognitive deficits in first-episode psychosis: a population-based study in S\u00e3o Paulo, Brazil","volume":"90","author":"Ayres","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0006","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2011.09.006","article-title":"Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study","volume":"133","author":"Chang","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0008","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.schbul.a007009","article-title":"Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychological treatment versus delay in treatment with antipsychotic medication","volume":"29","author":"de Haan","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/schbul\/sbx197","article-title":"Negative symptoms in early-onset psychosis and their association with antipsychotic treatment failure","volume":"45","author":"Downs","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-9964(99)00043-2","article-title":"Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data","volume":"40","author":"Edwards","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eurpsy.2014.01.007","article-title":"Impact of primary negative symptoms on functional outcomes in schizophrenia","volume":"29","author":"Fervaha","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2013.10.017","article-title":"Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders","volume":"24","author":"Foussias","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0013","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0014","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.schres.2009.09.022","article-title":"Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study","volume":"115","author":"Galderisi","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.euroneuro.2012.04.019","article-title":"Persistent negative symptoms in first episode patients with schizophrenia: results from the European first episode schizophrenia trial","volume":"23","author":"Galderisi","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0016","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0017","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/wps.20167","article-title":"The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia","volume":"13","author":"Galderisi","year":"2014","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(03)00097-5","article-title":"Correlates of cognitive deficits in first episode schizophrenia","volume":"68","author":"Heydebrand","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0019","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-244X-12-224","article-title":"Identifying persistent negative symptoms in first episode psychosis","volume":"12","author":"Hovington","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0021","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-matrics consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0022","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbv019","article-title":"The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics","volume":"41","author":"Leucht","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0023","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1192\/bjp.bp.116.197103","article-title":"Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis","volume":"210","author":"Lutgens","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0024","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.nmd.0000131804.34977.c1","article-title":"Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis?","volume":"192","author":"Malla","year":"2004","journal-title":"J. Nerv. Ment. Dis"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0025","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1176\/ajp.151.10.1417","article-title":"The deficit state in first-episode schizophrenia","volume":"151","author":"Mayerhoff","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2016.05.014","article-title":"Primary and persistent negative symptoms: concepts, assessments and neurobiological bases","volume":"186","author":"Mucci","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0027","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.euroneuro.2019.05.006","article-title":"A large European, multicenter, multinational validation study of the brief negative symptom scale","volume":"29","author":"Mucci","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0028","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4088\/JCP.08m04845yel","article-title":"Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the positive and negative syndrome scale","volume":"71","author":"Rapado-Castro","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2004.12.020","article-title":"Integrated treatment ameliorates negative symptoms in first-episode psychosis: results from the Danish OPUS trial","volume":"79","author":"Thorup","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2014.07.021","article-title":"Persistent negative symptoms after first episode schizophrenia: a 2-year follow-up study","volume":"158","author":"\u00dc\u00e7ok","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2020.03.010_bib0031","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20300730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20300730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:55:26Z","timestamp":1760378126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X20300730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":31,"alternative-id":["S0924977X20300730"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.03.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}